# SCH 42495 racemate

| | |
|---|---|
| **Cat. No.:** | HY-101682A |
| **CAS No.:** | 145841-10-7 |
| **Molecular Formula:** | $C_{20}H_{29}NO_4S_2$ |
| **Molecular Weight:** | 411.58 |
| **Target:** | Neprilysin |
| **Pathway:** | Metabolic Enzyme/Protease |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | SCH 42495 racemate is the racemate of SCH 42495. SCH 42495 is an orally active neutral metalloendopeptidase (NEP) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester proagent of SCH 42354[1]. |
| **$IC_{50}$ & Target** | NEP[1] |
| **In Vitro** | SCH 42495 selectively inhibits hydrolysis of leu-enkephalin and ANF ($IC_{50}$ of 8.3 and 10.0 nM, respectively) in vitro[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | SCH 42495 (30 mg/kg; oral gavage; twice daily) causes a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days[2].<br>Treatment with SCH 42495 (30 mg/kg; oral gavage; twice daily) leads to a decrease in cardiovascular remodelling secondary to chronic hypoxia in rats[2].<br>SCH 42495 (oral doses of 1, 3, or 10 mg/kg) produces significant reductions in blood pressure in DOCA-N a hypertensive rats of 22±6, 43±7, and 62±12 mm Hg, respectively[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Hypoxic rats[2] |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage; twice daily for 10 days |
| Result: | Caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy.<br>Led to a decrease in cardiovascular remodelling secondary to chronic hypoxia. |

## REFERENCES

[1]. Watkins RW, et al. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor. Am J Hypertens. 1993 May;6(5 Pt 1):357-68.

[2]. Thompson JS, et al. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clin Sci (Lond). 1994 Jul;87(1):109-14.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA